Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

How Caitlyn Krebs Built an AI Engine That Designs Drugs 5x Faster

Oct 16, 202534 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Caitlyn Krebs, Co-Founder and CEO of Nalu Bio, to share insights about AI-driven drug development, specifically targeting the endocannabinoid system (ECS) for therapeutic development in pain management, inflammation, and women’s health. Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00We all know the drug development process is long, it's costly, and it's high risk, but it's high reward as well. So we've leveraged generative AI in the preclinical setting. So we developed this generative AI platform, and it really is an engine to develop new chemical entities, so small molecules. And we've trained that model with 90,000 training compounds that bind to 25 GPCR receptors.

SPEAKER_01Hello, hello, and welcome to Pharma Sessions, a place for pharmaceutical leaders to come and learn from each other. I'm your host, Jonathan Kaskey. Technology and market trends are bringing change at an ever-accelerating rate, and no person, team, or company can afford to be left behind. Here, we dive into the strategies and tactics that our guests use to tackle these challenges and create new opportunities and how you can do the same in your own organization.

SPEAKER_01Today's episode of Pharma Sessions, I'm thrilled to welcome Caitlin Krebs, biotech entrepreneur and co-founder and CEO of NELU Bio. Caitlin is leading a team of innovators harnessing AI and the endocannabinoid system to create next generation therapeutics for pain, inflammation, metabolic health, and women's health. The question of how pharma can best use AI is super topical. And Caitlin is really innovating from a clinical standpoint. In this episode, we'll dive into how NELU Bio Bio leverages AI and generative modeling to design new chemical entities, the therapeutic potential of the ECS, and how innovation in biotech is evolving as we approach the upcoming$250 billion patent cliff.

SPEAKER_01Welcome to the show, Caitlin.

SPEAKER_00Thank you, Jonathan. Excited to be here today and excited for our conversation.

SPEAKER_01Absolutely. So we're talking on opposite coasts. I'm on the East Coast. You're on the West Coast. And I always start out my episodes with a little bit of a get to know you question, which quite honestly I stole from one of my favorite music podcasts, which is called Band Splane. If you're into music, it's a really good one, which she always asks as a good way to get to know people. It's 11 a.m. on the East Coast here. It's 818 on the West Coast. What have you had to eat so far today?

SPEAKER_00Ah, well, I started my morning with a 5 a.m. run because I love to exercise with some girlfriends. And then I've had a uh yogurt and some berries for breakfast and coffee. I have to have coffee to get my day started.

SPEAKER_01You start with the energizing workout and keep it fairly light and caffeinated to going.

SPEAKER_00Yes. How about you? What did you have for breakfast this morning?

SPEAKER_01I'm fairly similar, except I do have a little bit of stuff before I work out, including a uh like a three-ounce espresso. And then I do, you know, in this case, I went to the gym and then have my breakfast, my overnight oats, full coffee, and then roll right into the day.

SPEAKER_00I'm also an espresso fan. At CrossFit, they have a little espresso machine. So I do an espresso before I lift weights. So I'm with you there.

SPEAKER_01It's just a perfect little jolt to get you going.

SPEAKER_00It is. It is, absolutely.

SPEAKER_01We'll transition right into it then. But I mean, tell me a little bit about your background and what led you to this point where you're now the co-founder and CEO of a biotech.

SPEAKER_00I have been in the biotech and life sciences industry for the last 20 years. I'm a biologist by training. I grew up on the big island of Hawaii. So being out in nature, the environment, studying biology at Brown University, that really I think has generated this love of science. And my first real biotech job was at a modeling and simulation technology company called Intelos. We were building mechanistic models of biology in computers. This was 20 years ago.

SPEAKER_00We were simulating how drugs worked. We created what we called virtual patients at the time. Now they're called digital twins. So this company, Intelos, I actually still work with the CEO. He's an advisor to us here at Nalu. And that really fostered my love of biotechnology, modeling and simulation. And so that's what really drew me to co-found Nalu Bio. I'm a big believer in the endocannabinoid system, which most people haven't heard of.

SPEAKER_01To be honest, it took me some time to practice the pronunciation for my introduction. But why are you a big believer in the endocannabinoid system?

SPEAKER_00It was discovered in the 1990s. So it is the master regulator of all systems in our body. So of the eight major systems in your body, cardiovascular, metabolism, inflammation, this is the system that controls all of those and keeps your body at homeostasis. And I looked into it because in the like 2019, 2020, uh, CBD was booming. Everyone was using CBD. It was in coffee, it was in gummies, it was in, you know, cocktails.

SPEAKER_01Dog treats, right? Everything.

SPEAKER_00Exactly right. And so it binds to receptors in your body. And so I started looking into the biology and uncovered the endocannabinoid system. And it is, it's an untapped system in the pharmaceutical and drug development industry. So that's why I get excited about it. I actually saw a list of a hundred different potential disease opportunities for the endocannabinoid system. And I said, this is the next thing, this is the next science breakthrough.

SPEAKER_01Interesting. So you're taking your biology background plus the tech early on on the digital twin front and seeing in general, ECS we'll call it, as the opportunity, right? And then the idea is to essentially figure out the best paths forward to take advantage of that opportunity or to develop drugs that I should say use that to serve patients, right?

SPEAKER_00That's exactly right. Yeah, using technology to develop drugs faster, cheaper, and more precision engineered. With technology, you can really design kind of novel and very precision-engineered compounds.

SPEAKER_01Yeah, well, let's get right into that. Because I honestly think that that's the part that's the audience is going to find the most interesting, right? Because there's so much out there about all the different potential ways that people in pharma can use AI. And even in my own career, right, over the last five years, I've been involved with three different companies that do all totally legitimate things that are weren't even on the radar five years ago, 10 years ago, right? Whether it's one of them was around gathering and essentially gathering data and interpreting, kind of pulling out insights from that from an advisor standpoint for medical affairs, was around using AI to kind of better create documentation and drug labels and CMC documentation and the like.

SPEAKER_01And the one I'm currently at is all around AI, around kind of commercial data and using that to better align your sales teams and whatnot. But you're looking at this right now, you guys are purely pipeline company, right, from a pure clinical stage. So what are you seeing as kind of the major benefits and the opportunity for bringing AI in at the clinical and preclinical stage?

SPEAKER_00We all know the drug development process is long, it's costly, it's high risk, but it's high reward as well. And so we've leveraged generative AI in the preclinical setting. So we develop this generative AI platform, and it really is an engine to develop new chemical entities, so small molecules. And we've trained that model with 90,000 training compounds that bind to 25 GPCR receptors that we're interested in.

SPEAKER_00As you know, GPCR receptors are some of the most druggable targets in pharma. So 30 to 40% of drugs are targeting GPCR receptors on the market today. And so we're using the generative AI. So we feed the model with a compound, with a structure, and then the generative AI basically generates completely new chemical entities off of that, inspired by nature, but developed through AI to then bind to these receptors.

SPEAKER_01Because there's this idea of AI is developing essentially novel molecules, right? And then you as a company need to be able to produce those molecules for testing. So have you found that to be a challenge, or is that kind of baked into the requirements that you set up when you're when you're setting up the engine?

SPEAKER_00So throughout the life kind of cycle of our company so far, we've created three generations of molecules. So the first was inspired by naturally occurring cannabinoids. We still have some very smart chemists and they would make tweaks to the molecules where they thought we could improve upon nature. The second generation, we then use machine learning to look at specifically how they bind to the receptors of interest. So we're interested in receptors called C B1 and C B2, cannabinoid receptors.

SPEAKER_00And so we can model how these compounds bind. The third generation is completely made through AI. And so humans, we have mental chemists have mental models of how molecules should look. The AI does not. So to your point, they make these crazy looking molecules with chains and benzene rings. And so we've had to add into our modeling a synthesis, which means how you make the molecule, a synthesis complexity score from one to 10.

SPEAKER_00So 10 is very complex, one is very simple. And what I can tell you is we've only been able to synthesize basically scores from one to three. Above three, it's just too complex in the lab. It's too many steps, it takes too much time. So we can prioritize, based on what the model spits out, compounds that we can actually make. So it's a very good question.

SPEAKER_01That's fascinating. This question brings up past trauma for me because in college I was taking organic chemistry. I think I was I was trying to be a doctor, right? And I swear to God, the rules of chemistry did not apply. I couldn't make a molecule or get something to go properly to save my life.

SPEAKER_00So I remember those orgo labs. Yeah, they're long.

SPEAKER_01I was always the last one to leave the lab, and eventually, you know, the TA would just give up on me. That's really interesting. So then how do you find, I guess practically, you to get the people in your company, maybe I don't know if it's been a challenge to have them embrace it, but it seems like you're looking for a really select skill set of people who are both really, really good at the chemistry, but then can also handle the AI and machine learning. So how do you find people that fit that profile?

SPEAKER_00We have a couple gems in our company. One individual, Mehdi Hagust, he's a medicinal chemist. He knows cannabinoids, but he's really an AI expert. And so you have to find these gems in the industry that can go across chemistry, cannabinoids, and AI. And we've been able to find that. But you're absolutely right. We use a number of contract research organizations to do the chemistry for us. And you have to find very good ones who understand and who are willing to kind of push the envelope and really try some novel and new chemistry.

SPEAKER_00And I think that's part of the secret sauce. You know, we've been able to really synthesize some complex molecules.

SPEAKER_01Yeah. I mean, it's very interesting to me because I think that like a lot of the claims that AI companies make, I'll just speak for myself. You kind of look at it with some degree of skepticism, where like, oh, you can make these amazing apps and it'll it'll change the world. It's like, well, if you could really make a better app, why wouldn't you just make a better app instead of saying that you could like help others do it? But I think what's interesting here is clearly you believe that this is the process to make drugs faster and more efficiently because you're not saying, hey, we're going to become a platform that other companies can use for their clinical research.

SPEAKER_01You're trying to actually do it, which I think is really, really interesting. Should know this, but I'm just not aware of it. Like, what is the typical timeline for a clinic, you know, start to finish molecule to market drug these days? And what are you predicting that your approach will shave off of that?

SPEAKER_00Industry averages are about 10 years to develop molecules, sometimes much longer, depending on the space and the type of manufacturing process that you use. So for us, where we accelerate drug development, we believe we are five times faster at getting from target to basically drug candidate. And so typically that process is about four to five years, and we can do it in about a year. So we've really accelerated the process of getting from a target to a number of compounds, screening those compounds, prioritizing them, and then doing all the in vitro and in vivo work to get to a drug candidate.

SPEAKER_01And is your idea, maybe this is too much from a business perspective, but you know, I'll ask you because you're CEO, not CRO, right? So is the idea that this becomes a this ability to move faster and identify candidates faster becomes a long-term platform advantage for you all? Or is the idea, hey, there's an opportunity right now to innovate and to solve some problems and get to the market faster? Like what is the thinking around this?

SPEAKER_00It's a great question because as you highlighted, usually you're either a platform technology company or you're an asset, right? You're a pipeline company. There are a few companies out there who are doing both, like us. Insilico medicine is an example of that. We are very focused on our pipeline. We see this as a generative engine for us to develop extremely valuable assets, target the endocannabinoid system, go after some large unmet medical needs, endometriosis, post-surgical pain. So we're really focused on, as you say, using the technology for ourselves.

SPEAKER_00There is a point where others may want to be using this technology. And we're an early stage company, we're always open to collaboration.

SPEAKER_01Sure. I would have to imagine that other pharma companies. I can't imagine there's a pharmacompany out there that isn't being pressured to look at how to use AI in clinical. You name some of them, but what about the big players? Abvi has been out there. I think they they spent something like$40 million to develop a generative AI just for, again, the documentation, the different use case. But are there attempts by the larger pharma companies in this space that you're following?

SPEAKER_00Yes, pharma is, I mean, they're looking at AI, they're using it to your point. It's very good in documentation, submission, you know, aggregating data. There's no doubt about that. What we're doing is quite different, truly generating new chemical entities. So it is the discovery engine for us. Pharma is doing it. I can tell you, we have a molecule. It's called Nalo 33-4 for post-surgical pain. It is completely generated through AI. So I mentioned these three generations, right?

SPEAKER_00First one was chemistry, second was machine learning, third was generative AI. So it's completely generated through AI. It's now heading towards the clinic. There are not that many compounds out there like that. Pharma is working on it, but I can tell you, having talked to some of the large pharmaceutical companies, it's a bit underwhelming when you start drilling into exactly what they're doing on the AI piece of it. I think right now people are using it for very specific use cases where it adds value, but we're taking a different approach really holistically throughout drug discovery.

SPEAKER_01So, where's the industry? You had started the conversation talking about your work in digital twins, if that's a huge part of the drug development processes, the clinical trials and the human clinical trials and all that. Where are we with that? And with communicating with the FDA and their receptiveness to digital twins for parts of the clinical trials.

SPEAKER_00I was actually just listening to a webinar recently with a lawyer who works with the FDA. The FDA is accepting digital twins now as you build out a patient population, right? So there you can't replace the humans, right, with digital twins. But if you wanted to run a clinical study with, say, 500 patients, they might accept a percentage of those through these digital twins. When I was at Intelos, back to my early days with Tom Patterson, you can build out biological differences, you know, millions of them in the biology, in the physiology, just in the characteristics, the phenotypes of these patients digitally.

SPEAKER_00So that's where I get really excited. My vision is to have digital, basically quins of endometriosis patients. And so the compounds that we're making are very unique. They're non-hormonal, they're disease modifying, they're as good as opioids, they're as good as NSAIDs. Recruiting women to these endometriosis trials is a challenge. And so if you can have a digital version or population that you test on, is that I think is going to completely change the way we recruit for these trials, how long they take, the number that you need.

SPEAKER_00I'm super excited about that.

SPEAKER_01There's all sorts of things, even around reticence to participate once you know there's a trial going. If there's any additional types of validation you could do that make people think, hey, this might actually be safe, effective, solve my problem, that could only help, right? Because Absolutely. If you've been enjoying the conversations here on Pharma Sessions, you should know they're made possible by the team at Xunt. XSunt helps life sciences companies turn complex data into clear, actionable insight. For years, Xunt has made complicated data sets simple to help commercial, medical, and operations teams map what's happening, predict what's next, and make stronger decisions faster.

SPEAKER_01And now there's an added AI layer that makes everything work so much better. I was actually pretty jaded about some of the AI approaches I'd seen, but when XSunt showed me theirs, I actually left my job to come work for them. It's really awesome. So if you want to understand your market, your customers, or your performance with more clarity than ever, check out XSunt.com. That's XS-U-N-T.com. All right, let's jump back into the episode. So you're looking at, you said ECS is super broad in its potential.

SPEAKER_01How are you prioritizing your efforts?

SPEAKER_00I believe the endocannabinoid system is the next kind of GLP one, right? We've seen the GLP1 market explode. These compounds for GLP1 initially they were for diabetes. Then we, you know, saw complete change in the industry for obesity. Now we know they have cognitive benefits, cardiovascular benefits. So I see the ECS as the next GLP1 kind of unlock for biotech and for the industry because, to your point, it plays a role in all major systems, cardiovascular, inflammation.

SPEAKER_00And so when we think about prioritizing drugs for us, first it's about the endocannabinoid biology. Like, does the biology lend to efficacy and pain, inflammation for endometriosis, disease modification? So we look at the ECS biology first, then we look at the unmet need. Is this a large unmet need that we believe we can address? And then we really look at, you know, the market potential for us. Is this a market that we're interested in?

SPEAKER_00Do we think pharma ultimately will be interested in these molecules? So it's really three factors ECS, the patient community, and then the pharma and kind of market potential of these compounds.

SPEAKER_01It's very much all that sounds of everything you've talked today, that that's kind of sounds like the most traditional approach. The idea is just to use this, the tech and the AI that we talked about to get there faster. Is that correct?

SPEAKER_00That's exactly right. It's using the tech and kind of unlocking a system that really hasn't been focused on. And the reason why there's less focus, I believe, in pharma is cannabinoids come with a stigma, right? Naturally occurring cannabinoids come with a stigma, whether it's CVD, whether it's THC, you know, marijuana. We're not doing any of that. We are inspired by nature, but we're creating these new chemical entities. And I think that's really the uniqueness of Nalobio and why I believe we're an outlier, why I believe we're gonna really change the landscape in this class of molecules.

SPEAKER_01Is such a challenge going after something so broad, the endocannabinoid system, where again, it sounds like there's so much potential in all of these different areas. I'm trying to think of the right way to phrase this. It's almost overwhelming, right? And at some point, just the way that our system works, you need to create a pick a very specific indication, like post surgery, you know, pain recovery or whatever. How do you weigh that where you're saying, yes, we think we can be very effective in this particular space versus something like general inflammation, right?

SPEAKER_01Which might be much less defined, but maybe much more prevalent.

SPEAKER_00I'll give you an example in endometriosis, about 50% of women who have endometriosis. Are already using cannabinoids. So not an FDA approved, right? They're getting this at a dispensary or they're getting it in a grocery store. 70 to 80% of women show reduction in pain. So pain efficacy using cannabinoids. But as you know, THC gets you high. You can't drive, you can't work. So these women, even in countries where cannabis is illegal, they will still use it.

SPEAKER_00It improves the pain. It doesn't change the disease modification, which is what our precision-engineered compounds can do. But there are a number of other outcomes that they look at. They look at sleep, they look at anxiety, they look at depression. So these women who are using naturally occurring cannabinoids, they're working for the pain, but they're also working for other endpoints as well. And so our strategy is quite unique actually for endometriosis. Our endpoint is pain, but the disease modification is actually an exploratory endpoint for us.

SPEAKER_00And we will publish on that and we will show physicians that we can actually shrink the lesion. So we're doing the traditional approach, but we're also innovating in the exploratory endpoints. And that's how we believe we'll get some of these additional benefits that you're talking about sleep, anxiety, depression.

SPEAKER_01That's fascinating. I remember being at a conference once and somebody, it was a market access person, was talking about this challenge. And he was like, when you're going for say formulary status, like how do you quantify the value of being able to walk up the stairs without pain? There's all these benefits, but it seems like people have essentially found their own way, however, they've gotten there into this. At least the number you said was 50% of people have found their own way here. You're hopefully setting up a prescription pathway where they can be getting those benefits and also solving the problem itself.

SPEAKER_00That's right. And that's why we got so excited about you, you asked, you know, why we chose endometriosis. The market's already there. Women are already using these compounds. We're just making better precision-engineered, disease-modifying compounds that can be prescribed via a physician through the and approved through the FDA. So really focused on the consistency, the quality, and the regulatory lens that the FDA brings to these molecules.

SPEAKER_01So endometriosis, I mean, I think historically, correct me if I'm wrong, but women's health is often underrepresented in drug development. So why is that? And how is this new application of AI, these types of insights going to address these gaps?

SPEAKER_00So women's health is underfunded, it's understudied. As you know, women were included. They weren't required to be in clinical trials until 1993, which is just mind-blowing to me. When we run studies, you know, in endometriosis, we have to ask for female mice. You know, they usually use male mice. So it's just, it is really underserved, underrepresented. And so we obviously believe, you know, being a female founder, you know, only 2% of venture dollars go to female founders.

SPEAKER_00So bringing to light women's health and addressing women's health is really important. And the interesting thing about the endocannabinoid system is it's uniquely suited for women. We actually have more receptors than men. So in the lesions themselves, we have more CB1 and CB2 receptors. We metabolize cannabinoids and molecules like this more slowly, which is a good thing. It lasts your body longer. So women, and there's a hormone interplay between the AECS.

SPEAKER_00It regulates reproduction. So there's a hormone interplay. So it's uniquely suited for therapeutic development in women's health needs. And so that's why, you know, we're excited about endometriosis.

SPEAKER_01I uh I had not heard that about the mice before.

SPEAKER_00No, you wouldn't think about it until you really dig into it.

SPEAKER_01Wow. Okay. And so then how is your, you know, as you said, 2% of funding going to female founders? Obviously, bringing a drug to market is a hugely expensive process. How have you found the fundraising and the venture capital side of things?

SPEAKER_00So, you know, it has still been very challenging. So we've raised a seed in the series A. We're really going after endometriosis and women's health as our first indication. Post-surgical pain is our second. So we're more broadly focused on pain, inflammation, immunology, and metabolic diseases. So we're broader than women's health. But, you know, my challenge is, and I kind of challenge the industry in women's health, is that there are a lot of women's health venture funds that are early, seed Series A, they're small funds.

SPEAKER_00We do not have yet these large women's health funds. And so that's my challenge to the industry is let's find a group that can write sizable checks and lead rounds that are later staged. There's this gap, unfortunately, in the market today.

SPEAKER_01Well, I'm hopeful for you that all of this work that you're doing to, I mean, when you're talking about de-risking the clinical trial process, you would think that would be very appealing to potential investors to move faster and in a less risky manner. So I'm hopeful that your approach can be fruitful for you all.

SPEAKER_00Thank you. I appreciate that. As an entrepreneur, it just takes a lot of grit, a lot of persistence, some really good storytelling. And but it's, you know, at the end of the day, the market is there. It's a large unmet need, and investors are seeing that.

SPEAKER_01All right, let me ask you a couple final questions here. So if let's say you're sitting in your home office or you're traveling around, you work for a pharma company in clinical, one to three things you might suggest people do today to help people bring some innovation to their groups.

SPEAKER_00First of all, just reading up on AI. There's so many different, you know, articles that you can learn about different approaches to AI, trying it, you know, just playing around with it. We're part of NVIDIA's inception program. Nvidia has a number of really good off-the-shelf software and tools. One is called Bionemo for drug discovery and development. Going to events, right? Meeting other companies, entrepreneurs that are using it, comparing kind of the earlier stage innovative companies to what pharma is doing.

SPEAKER_00Those are the things that I would do to kind of stay relevant with the industry. It's changing so fast. I love technology. So I also go to a lot of events that are just true kind of software and tech. And we can learn a lot, I think, cross-industry as well. I think biotech can learn a lot from tech on that side.

SPEAKER_01On so many things, because I mean, so much of it is unique to the biotech space, but there's a lot, always believed and probably will continue to believe this that pharma biotech can do if they just kind of look at what's out there, what other companies that are in less regulated spaces are able to do, because they have so much more freedom to experiment, and then what makes sense to bring home, right? Where you don't necessarily need to be on everything cutting edge, but if you're staying on top of what people in other industries are doing, that can that can really be a big advancement for where a lot of companies are right now.

SPEAKER_00Yeah, I completely agree. Um, one of the groups that I work for was Rock Health a number of years ago, which is a digital health incubator and accelerator and an early seed stage fund. And that was a lot of entrepreneurs coming out of tech and moving into healthcare. You know, and I was the biotech healthcare, and so they were always breaking the rules and I was always reminding them of how to stay in the biotech lane. I think the right solution is somewhere in between, right? You want to push the edge and you want to innovate, but you also obviously, from a regulatory perspective, have to stay within some parameters.

SPEAKER_00So I love entrepreneurs that bring in other ideas into biotech and healthcare. I think it's needed.

SPEAKER_01Excellent. All right, let's end on a fun one. So just outside of your professional work, what personal philosophy, habit, what do you think has most influenced your approach to innovation and leadership in biotech?

SPEAKER_00Biotech is a long game, right? It's a long, you know, you're not building a software company in a couple of years and flipping it and exiting. So, you know, I see it really as an endurance sport. I love to do endurance sports. I do triathlons, I do marathons. And so I just see really it's focusing on the long game and focusing on mental health and wellness, making sure that there's a balance between work and outlets. And so I find a lot of pleasure and exercise just because it actually helps with my mental health.

SPEAKER_00I obviously have a lot of conviction around the endocannabinoid system. I am committed to developing therapeutics. I think it's the next GLP one category. And so that conviction really drives me to continue to run the marathon and play the long game.

SPEAKER_01I love it. I'm watching my older daughter right now, is doing cross-country. She just started. She's in, she's in sixth grade, and I'm getting so much pleasure out of watching her because it is, it's like I've done some distance running myself. It's like in any any day you go out, it might not be your best day. Maybe it is your best day. It doesn't really matter, but it's like you go out there and you do what you can, and then you come back and you try again the next day. And I just think there's something very, I don't know, positive about that, where it's like, well, I'm just gonna go out there and whatever it is, I'm gonna find what the progress is. And yeah, I think it's applicable in a lot of spaces.

SPEAKER_00I agree. I mean, I also do CrossFit weightlifting, and I find that actually the days when I'm tired and I'm not feeling well and I push through, those are actually the most transformative days versus the good days. They're like, okay, I got this. But when you're like, this deadlift is really hard today, I'm like, I can do this.

SPEAKER_01But that's when you feel proud of yourself, right? Anybody can do it when they want to do it. It's when you don't want to do it. That's what you have to be proud of. Excellent. Caitlin, thank you so much. Really appreciate speaking with you today.

SPEAKER_00Jonathan, thank you for your time. Thank you for having me. It was a great conversation.

SPEAKER_01And that's a wrap on today's episode of Pharma Sessions with me, Jonathan Kaske. If you enjoyed today's conversation, don't forget to hit follow or subscribe and share it with someone else in the pharma world who might need to hear it. For more on pharma trends, career growth, and business strategies, connect with me, Jonathan Kaske, on LinkedIn. Until next time, thanks for listening.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode